Human GPRC5D-GFP Virus-Like Particles

Human GPRC5D-GFP Virus-Like Particles (VLPs) are highly specialized reagents designed to present the human G protein-coupled receptor class C group 5 member D in its native, multi-pass transmembrane conformation. GPRC5D is a critical biomarker and therapeutic target significantly upregulated on the surface of malignant plasma cells in multiple myeloma. These VLPs are engineered by overexpressing the GPRC5D protein—fused with a Green Fluorescent Protein (GFP) reporter—in mammalian host cells, such as HEK293, where they self-assemble and bud from the plasma membrane. This biological process ensures that the receptor maintains its complex seven-transmembrane architecture and essential post-translational modifications within a stable lipid bilayer environment. The integration of the GFP tag facilitates direct visualization, accurate concentration determination, and simplified experimental monitoring, providing a robust and non-infectious alternative to whole-cell preparations for studying this challenging membrane protein.

The primary application of these VLPs lies in the discovery and characterization of advanced biologics, including monoclonal antibodies, bispecific T-cell engagers (BiTEs), and CAR-T therapies. They serve as an ideal antigen source for high-throughput screening platforms such as phage display and yeast display, where the preservation of conformational epitopes is vital for selecting high-affinity functional candidates. In biophysical analysis, GPRC5D-GFP VLPs are utilized as soluble antigens for measuring binding kinetics and affinity via Surface Plasmon Resonance (SPR) and Biolayer Interferometry (BLI), offering a superior signal-to-noise ratio compared to crude cell lysates. Additionally, these particles are highly effective immunogens for animal immunization protocols and can be employed in flow cytometry (FACS) to validate the binding specificity of candidate molecules. By mimicking the natural cell surface environment, these VLPs bridge the gap between initial in vitro discovery and complex cell-based validation, significantly accelerating the development of targeted immunotherapies for hematological malignancies.